STEVEN P. ANDERSON, D.V.M., Ph.D, D.A.B.T

**** ****** ****** *****

Matthews, NC 28105

Home: 980-***-****

Cell: 225-***-****

adj25j@r.postjobfree.com

EDUCATION

Ph.D., Comparative Biomedical Sciences, Minor: Biotechnology

North Carolina State University, Raleigh, NC

2001

Residency in Anatomic Pathology

North Carolina State University, Raleigh, NC

1994

D.V.M., Veterinary Medicine

Oklahoma State University, Stillwater, OK

1992

B.S., Zoology

University of Oklahoma, Norman, OK

1985

EMPLOYMENT HISTORY

Employer

Position Title

Dates

Albemarle Corporation

Toxicology Advisor II

2012 - Present

Merial Limited

Director/Preclinical Leader

2008 - 2012

Bridge Pharmaceuticals

Senior Study Director & Toxicologic Pathologist

2007 - 2008

PPD, Inc.

Associate Director, Preclinical Development

2006 - 2007

Talecris Biotherapeutics

(Formerly Bayer

Biologics)

Principal Scientist I

(Pathology/Toxicology)

2003 - 2006

GlaxoSmithKline

Research Fellow in Investigative Pathology & Toxicology

1999 - 2003

SUMMARY OF EXPERIENCE

Dr. Anderson has over twenty years of experience in preclinical pathology, toxicology and pharmacology research. With a Ph.D. in Comparative Biomedical Sciences (Molecular Biology and Genetics), a veterinary degree from Oklahoma State University, a residency in anatomic pathology, and board-certification in toxicology, Dr. Anderson has served in management positions in the chemical, contract research, pharmaceutical, and biopharmaceutical industries where he has designed, implemented and managed a wide variety of preclinical safety studies. Dr. Anderson has extensive experience in designing in vitro and in vivo protocols, performing risk analyses and generating the pharmacology and toxicology sections of IND- and PMN-supporting regulatory submissions. In addition, he has experience with Ecotoxicology and Environmental Fate Studies. He is proficient in FDA NDA submissions, FDA INAD submissions, REACH regulations, IUCLID dossier preparation, EPA Design for the Environment, OECD QSAR Toolbox and regulatory compliance. His therapeutic areas of expertise include: Cancer, Infectious/Parasitic, Central Nervous System, Endocrine/Metabolic, Ophthalmic, Hematology, Respiratory, Biologics and Recombinant Proteins. Dr. Anderson is a member of the Society of Toxicology, the American College of Toxicology, the North Carolina Society of Toxicology, the Toxicology Forum and the Society for Risk Analysis. He is a reviewer for Toxicology and Research Applications.

EXPERIENCE

Albemarle Corporation, Charlotte, NC (2012 – Present)

Toxicology Advisor II, Government and Regulatory Affairs

Serve as a Toxicology Advisor for a medium-sized ( > 5,000 employees), worldwide, specialty chemical company. Responsibilities include serving as the primary toxicologist for the Bromine Specialties (fire safety, oilfield drilling, biocides, pharmaceuticals) and Fine Chemistry Services (pharmaceuticals, agrichemicals, lubricants and specialty chemicals) Global Business Units. Duties include supporting research, development, product stewardship and regulatory affairs, with design and oversight of contracted physicochemical characterizations, and environmental fate, mammalian, genetic, and environmental toxicology studies. Provide support for registration of new chemicals (US, Canada, Asia, Europe) and stewardship for maintenance of currently marketed chemicals. Very familiar with TSCA, FIFRA, ICH and REACH regulations and guidelines. Lead toxicologist in setting Occupational Exposure Banding and active pharmaceutical ingredient (API) clean-out limits. Serve as primary company toxicology representative for the North American Flame Retardant Alliance (NAFRA). Extensive experience with QSAR modeling and New Approach Methodologies (NAMs).

Merial Limited, Duluth, GA (2008 – 2012)

Preclinical Leader (Director), Global Safety Assessment

Responsible for the planning and supervising of preclinical proof-of-concept/efficacy projects and the facilitation of in vivo and in vitro preclinical safety screening projects of formulations and molecules in discovery, research or pre-development. These projects represented components of one or more major worldwide pre-development programs. Provided preclinical technical leadership in the Discovery Research group for pharmaceutical opportunity evaluations. Managed safety programs within Development Projects programs, authored risk assessments and supported in-line development as requested. Well-versed in EPA TSCA, FIFRA and FDA CVM regulations and guidelines. Supervised others assigned to projects. Responsible for coordination and maintenance of resource and financial budgets for the preclinical projects involved. Provided pathology support. IACUC member from 2010 - 2012.

Bridge Laboratories, Gaithersburg, MD (2007 -2008)

Sr. Study Director and Toxicologic Pathologist

Served as Study Director, Pathologist and Clinical Laboratory Animal Veterinarian for GLP and exploratory toxicology and pharmacology studies. Responsibilities included:

Managing the conduct of preclinical toxicology studies involving preparation of study protocols and animal use forms, observation of animals throughout study cycle, review of study data for scientific quality, and preparation of final reports.

Responding to Quality Assurance audits

Communication with study Sponsors.

Developing and reviewing new procedures, technologies, and SOPs as required.

Interpretation of clinical pathology data and generation of reports.

Supervision of Necropsy staff, evaluation of gross lesions, and preparation of reports.

Evaluation of histologic slides from preclinical toxicology studies and preparation of reports.

Project manager for a major NIH contract.

Serve as one of several clinical laboratory animal veterinarians responsible for the medical care of non-human primates, dogs, rats, mice, rabbits, and guinea pigs.

PPD, Inc., Morrisville, NC (2006-2007)

Associate Director, Preclinical Development

Responsible for designing and managing preclinical development programs from early discovery through regulatory submission for internal compound partnering programs as well as client programs. Responsible for identifying required preclinical studies for regulatory submissions, ensuring the preclinical program supports the manufacturing program and the intended clinical program, managing all aspects of the preclinical studies, and for generating the pharmacology/toxicology section of submissions.

Lead and manage PPD Preclinical Programs:

Worked as part of project team to develop preclinical development programs and managed those

programs across all laboratories (within and outside of PPD)

Reviewed and analyzed preclinical data (toxicology, pharmacology, and drug metabolism data)

Prepared preclinical development plans necessary to support intended clinical program and

ensured successful IND, NDA (or other regulatory submission)

Tracked preclinical projects: track studies and timelines, and metrics

Prepared preclinical protocols and reports

Worked with multidisciplinary team of scientists (chemists, pharmacologists, toxicologists,

biochemists) to ensure preclinical programs were fulfilling objectives and scientific issues were addressed

Prepared pre-meeting packages (e.g., pre-IND packages) and defended preclinical programs to FDA

Prepared pharmacology/toxicology sections of INDs

Led subgroup meetings and ensured an appropriate communication flow

Served as primary PPD contact for Sponsors on preclinical programs

Tracked progress and metrics of projects. Maintained current knowledge of status of assigned projects relative to preclinical programs and regularly updated senior management.

Tracked finances of preclinical programs and communicated to Finance

Talecris Biotherapeutics, Inc. (formerly Bayer HealthCare), RTP, NC (2003-2006)

Principal Research Scientist (Toxicology, Pathology and Pharmacology)

Designed, implemented and managed preclinical safety studies for new biological entities. Provided histopathology expertise for all preclinical studies.

Developed and supervised 3 scientists charged with developing and implementing novel pharmacodynamic and pharmacokinetic studies in various animal species.

Provided risk assessments and generated preclinical sections of regulatory documents.

Served as preclinical representative on cross-functional drug development teams.

Generated a toxicologic risk analysis showing negligible health risk to patients receiving a therapeutic produced by a process associated with a manufacturing deviation. Resulted in release of $30M of product that had been placed on hold.

Streamlined an in vivo protocol designed to assess better drug efficacy by increasing through-put 5-fold and decreasing compound requirements 100-fold.

Enlisted and consulted with subject matter experts, then designed, implemented, and managed a $4M preclinical development plan for a therapeutic that was delivered by a novel route of administration.

Prepared preclinical sections of regulatory submission documents (e.g., CTDs, INDs, IBs).

GlaxoSmithKline, RTP, NC (1999-2003)

Research Fellow in Molecular Pathology, Safety Assessment

Performed an integral function as part of a team formed to evaluate and implement genomic, bioinformatic, and molecular biological techniques for predicting toxicity and understanding mode of toxic action of new chemical entities. Research results were published in 8 manuscripts.

Acting as a member of a large cross-functional team, assisted in the design and execution of experiments comparing rat and non-human primate adaptations after acute and subchronic exposure to a class of PPAR agonists.

CIIT Centers for Health Research, RTP, NC (1994-1999)

Postdoctoral Trainee, Cancer Research Program

Carried out doctoral thesis research on the molecular mechanism of PPAR-agonist-induced hepatocarcinogenesis in rodents. Research led to 7 peer-reviewed publications and 2 book chapters.

North Carolina State University, College of Veterinary Medicine, Raleigh, NC (1992-1994)

Resident in Anatomic Pathology

Carried out gross, histologic, and ultrastructural examinations of domestic and laboratory animals.

Recognized an internal deficiency for training in comparative pathology. Established connection with the pathology department at UNC medical school and served as the first veterinary pathologist to train in human pathology at that institution.

UNC School of Medicine, Chapel Hill, NC (1993-1993)

Visiting Resident in Anatomic Pathology

Oklahoma State University, College of Veterinary Medicine, Stillwater, OK (1989-1992)

Research Associate, Biochemistry

M.D. Anderson Cancer Center, Houston, TX (1991-1991)

Visiting Researcher, Cell Biology

PROFESSIONAL CERTIFICATIONS

European Registered Toxicologist, 2019 - present

UK Registered Toxicologist 2019 - present

Diplomate, American Board of Toxicology, 2005, 2010, 2015, 2020

Certified Emergency Medical Responder, State of Louisiana

Eligible for Board Certification in Veterinary Pathology (Anatomic)

Certificate in Operations Management, Louisiana State University, May 2019

Certificate in Leadership & Management, Louisiana State University, July 2018

Certificate in Business Project Management, Louisiana State University, July 2018

Leadership Certificate, North Carolina State University, May 1997

Certificate of Completion, Veterinary Anatomic Pathology Residency, May 1992

Oklahoma State Veterinary Medical Board, April 1992

National Veterinary Medical Board, January 1992

AWARDS AND HONORARIA

Society of Toxicologic Pathology Young Investigator Award, 1998.

Student Travel Award, Society of Toxicologic Pathologists, 1998 Annual Symposium,

Vancouver, BC

NIH Individual National Research Service Award, 1997 – 2000

Postdoctoral Fellowship Award, Chemical Industry Institute of Toxicology, 1992 – 1999

Who’s Who in American Colleges and Universities, 1991

Phi Zeta (Veterinary Honor Society), 1991

Hill’s Company Veterinary Student Scholarship, 1991

Salisbury Scholarship, OSU CVM, 1991

Oklahoma City Obedience Club OSU CVM Scholarship, 1991

CONTINUING EDUCATION COURSES AND TRAINING

1.NTP Workshop: “Converging on Cancer”. US EPA, Washington D.C., April 29-30, 2019.

2.Continuing Education Course: “Conducting Systemic Review in Toxicology – Why, When, How?” Society of Toxicology, Baltimore, Maryland, March 10, 2019.

3.Continuing Education Course: “Industrial Application of Computational Toxicology in the 21st Century,” Society of Toxicology, Baltimore, Maryland, March 10, 2019.

4.Dose-Response Boot Camp®. Toxicology Excellence for Risk Assessment. Cincinnati, OH, September 24 – 28, 2018.

5.Certificate in Operations Management, Louisiana State University, May 2019.

6.Certificate in Leadership and Management, Louisiana State University, Baton Rouge, LA, September 6, 2018.

7.Certificate in Business Project Management, Louisiana State University, Baton Rouge, LA, September 6, 2018.

8.QSAR Application Toolbox, v. 4.1, Basic Training Workshop, Barcelona, Spain. November 20 - 21, 2017.

9.QSAR Application Toolbox, v. 4.1, Advanced Practical Training Workshop, Barcelona, Spain. November 22 - 24, 2017.

10.“Enhancing Organizational Performance”, Professional Development Course, Louisiana State University, Baton Rouge, LA. May 20 – 21, 2019.

11.“Essential of Operations Management”, Professional Development Course, Louisiana State University, Baton Rouge, LA. March 27 - 28, 2019.

12.“Essentials of Project Management”, Professional Development Course, Louisiana State University, Baton Rouge, LA. September 5 - 6, 2018.

13.“Project Change Control and Cost Management”, Professional Development Course, Louisiana State University, Baton Rouge, LA. November 7 - 8, 2018.

14.“Quality Assurance Essentials”, Professional Development Course, Louisiana State University, Baton Rouge, LA. September 13, 2018.

15.“Techniques for Project Development”, Professional Development Course, Louisiana State University, Baton Rouge, LA. March 17 - 18, 2018.

16.“Estimation & Cost Benefit Analysis”, Professional Development Course, Louisiana State University, Baton Rouge, LA. April 4 - 5, 2018.

17. “Fundamentals of Supervision”, Professional Development Course. Louisiana State University, Baton Rouge, LA. August 28 - 30, 2017.

18.“Finance for Non-Financial Managers”, Professional Development Professional Development. Louisiana State University, Baton Rouge, LA. September 25 - 26, 2017.

19.“Public Speaking: Personal and Professional”, Professional Development Course. Louisiana State University, Baton Rouge, LA. October 19, 2017.

20.“Developing Your Managerial Effectiveness”, Professional Development. Louisiana State University, Baton Rouge, LA. November 6 - 7, 2017.

21.“Effective Writing for Business and Technical Professionals”, Professional Development. Louisiana State University, Baton Rouge, LA. November 2, 2017.

22.REACH Summer School. Cambridge, England. August 15 – 19, 2016.

23.U.S. EPA Sustainable Futures Training Workshop. Washington, DC. July 2013.

24.Continuing Education Course: “Emerging Approaches in Genetic Toxicology for Product Development”. Society of Toxicology, Baltimore, Maryland. March 12, 2017.

25.Continuing Education Course: “Adverse Outcome Pathway (AOP) Development and Evaluation”. Society of Toxicology, New Orleans, LA. March 13, 2016.

26.Continuing Education Course: “23rd Annual Genotoxicity workshop”. BioReliance, Bethesda, MD.

27.“Introduction to GLP Regulations”, Bayer HealthCare, Research Triangle Park, NC, January 05, 2005.

28.“Management and Leadership Development Program”, Bayer HealthCare, Raleigh, NC 2004 – 2005.

29.“Introduction to GMP”, Bayer HealthCare, Clayton, NC, February 2004.

30.SIMCA-P, GlaxoSmithKline, Inc, Research Triangle Park, NC, November 11-12, 2002.

31.Spotfire Advanced Biology, GlaxoSmithKline, Inc, Research Triangle Park, NC, November 7, 2002.

32.Introduction to Spotfire, GlaxoSmithKline, Inc, Research Triangle Park, NC, November 7, 2002.

33.Rosetta Resolver Gene Expression Analysis Software Workshop, GlaxoSmithKline, Inc, Research Triangle Park, NC, June 2002.

34.Seven Habits of Highly Successful People Workshop, FranklinCovey, Research Triangle Park, NC, May 2001.

35.Keystone Symposium: Molecular Toxicology, Toxicogenomics, and Associated Bioinformatics Applied to Drug Discovery, Santa Fe, NM, January 2000.

36.GlaxoWellcome Drug Discovery & Development Process, GlaxoWellcome, Inc., Research Triangle Park, NC, October 1999

37.What Matters Most Time Management Workshop, FranklinCovey, Raleigh, NC, June 1999.

38.From the Promise to the Pipeline - A Symposium on New Technologies to Accelerate Drug Discovery and Development, PE Biosystems, Research Triangle Park, NC, November 1997.

39.Descriptive Veterinary Pathology, Armed Forces Institute of Pathology, Bethesda, MD, June 1997.

40.Leadership Development Workshops (37 hrs), North Carolina State University, Raleigh, NC, May 1997.

41.Good Laboratory Practices for Scientists, West Coast Training Institute, Research Triangle Park, NC, April 1997.

42.Good Laboratory Practices for Study Directors, West Coast Training Institute, Research Triangle Park, NC, April 1997.

43.Gross Morbid Anatomy of Diseases of Animals, Armed Forces Institute of Pathology, Bethesda, MD, March 1997.

44.Pathology of Laboratory Animals, Armed Forces Institute of Pathology, Bethesda, MD, August 1995.

45.Persuasive Presentations Workshop, Professional Eloquence, Inc., Research Triangle Park, NC, April 1995.

.

PROFESSIONAL AFFILIATIONS

Society of Toxicology

American College of Toxicology

Toxicology Forum

Society for Risk Analysis

PRESENTATIONS

Laughter A, Anderson SP, Dunn C, Yoon L, Swanson C, Chandraratna R, Stulnig TM, Steffensen KR, Gustaffson J, and Corton JC (2005). Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver. Society of Toxicology 44th Annual Meeting, New Orleans, LA, March 2005.

Anderson SP, Howroyd P, Liu J, Qian X, Bahnemann R, Swanson C, Kwak M, Kensler TW, and Corton JC (2005). The transcriptional response to a peroxisome proliferator-activated receptor alpha agonist includes increased expression of proteome maintenance genes. Society of Toxicology 44th Annual Meeting, New Orleans, LA, March 2005.

Corton JC, Apte U, Anderson SP, Limaye P, Yoon L, Latendresse J, Everitt J, Voss KA, Kimbrough C, Wong JS, Gill SS, Chandraratna R, Kwak M, Kensler TW, Stulnig TM, Steffensen KR, Gustaffson J, and Mehendale HM (2005). Role of PPAR-alpha in caloric restriction effects in the mouse liver. Society of Toxicology 44th Annual Meeting, New Orleans, LA, March 2005.

Anderson SP, Pamarthi M, Bergstrand K. College of Agriculture and Life Sciences Lecture, North Carolina State University, Raleigh, NC.

Anderson SP. Transcriptome Profiling: A Tool for Understanding the Biologic Effects of the PPAR Agonists. Triangle Array User’s Group (TAUG). North Carolina Biotechnology Center, Research Triangle Park, NC, August 2002.

Anderson SP. Gene Expression Profiling of Peroxisome Proliferator-Induced Hepatocarcinogenesis. Schering-Plough Research Institute, Kenilworth, NJ, October 2001.

Anderson SP. Using Gene Expression Profiles to Predict Mechanisms of Hepatotoxicity. GlaxoSmithKline Research and Development, Upper Merion, PA, October 2000.

Anderson SP, Corton JC, Cattley RC, Fan L-Q, Stauber AJ, Miller RT, and Gonzalez FJ. Regulatory Effects of Peroxisome Proliferators in Carcinogenesis and Acute Inflammatory Responses. CIIT Scientific Open House, Research Triangle Park, NC, October 1998.

Cattley RC, Anderson SP, Christensen JG, Corton JC, Miller RT, Peters JM, and Gonzalez FJ. Receptor Activation in Carcinogenesis by Peroxisome Proliferators. CIIT Scientific Open House, Research Triangle Park, NC, October 1998.

Corton JC, Cattley RC, Lapinskas PJ, and Anderson SP. Receptor-Mediated Carcinogenesis: Mode of Action for Peroxisome Proliferator Chemicals. CIIT Scientific Open House, Research Triangle Park, NC, October 1997.

Miller RT, Anderson SP, Corton JC, and Cattley RC. (1998). TGF -LAP, TGF RII, and cyclophilin-40 expression in peroxisome proliferator-induced adenomas in rat. FASEB Summer Conference: Cellular and Molecular Mechanisms for Liver Growth Regulation, Snowmass, CO, August 1998.

Corton JC, Anderson SP, Miller RT, Mode A, Gustafsson J-A, Cattley RC. Molecular Analysis of Peroxisome Proliferator-Induced Rat Liver Tumors (extended abstract), Peroxisome Proliferator Meeting, Stockholm, Sweden, June 1997.

PUBLICATIONS

Manuscripts (Peer-reviewed)

Smith CJ and Anderson SP (2017). High discordance in development and organ site distribution of tumors in rats and mice in NTP two-year inhalation studies. Toxicology Research and Application. 1:1-22.

Vallanat B, Anderson SP, Brown-Borg HM, Ren H, Kersten S, Jonnalagadda S, Srinivasan R, Corton JC (2010). Analysis of the heat shock response in mouse liver reveals transcriptional dependence on the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha). BMC Genomics, 7: 11-16.

Xiao S, Anderson SP, Swanson C, Bahnemann R, Voss K, Stauber A, and Corton JC (2006). Activation of peroxisome proliferator-activated receptor-alpha enhances hepatocyte apoptosis. Toxicol. Sci., 92: 368-377.

Voss KA, Liu J, Anderson SP, Dunn C, Miller JD, Owen JR, Riley RT, Bacon CW, and Corton JC (2006). Toxic effects of fumonisin in mouse liver are independent of the peroxisome proliferator-activated receptor . Toxicol. Sci., 89: 108-119.

Cariello NF, Romach B, Colton H, Ni H, Yoon L, Falls JG, Casey W, Creech D, Anderson SP, Benavides GR, Hoivik DJ, Brown R, and Miller RT (2005). Gene expression profiling of the PPAR agonist ciprofibrate in the cynomolgus monkey liver. Toxicol. Sci., 88: 250-64.

Anderson SP, Howroyd P, Liu J, Qian X, Bahnemann R, Swanson C, Kwak MK, Kensler TW, and Corton JC (2004). The transcriptional response to a peroxisome prolifererator-activated receptor-alpha agonist includes increased expression of proteome maintenance genes. J. Biol. Chem., 279: 523**-*****.

Anderson SP, Dunn C, Laughter A, Yoon L, Swanson C, Stulnig TM, Steffensen KR, Chadraratna RA, Gustafsson JA, and Corton JC (2004). Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor-alpha, retinoid X receptor, and liver X receptor in mouse liver. Mol. Pharmacol., 66: 1440-1452.

Corton JC, Apte U, Anderson SP, Limaye P, Yoon L, Latendresse J, Dunn C, Everitt JI, Voxx KA, Swanson C, Kinbrough C, Wong JS, Gill SS, Chandraratna RA, Swak MK, Kensler TW, Stulnig TM, Seffensen KR, Gustaffson JA, and Mehendale HM (2004). Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors. J. Biol. Chem., 279: 462**-*****.

Hoivik DJ, Qualls CW Jr, Mirabile RC, Cariello NF, Kimbrough CL, Colton HM, Anderson SP, Santestefano MJ, Morgan RF, Dahl RR, Brown AR, Zhao Z, Mudd PN Jr, Oliver WE Jr, Brown HR, and Miller RT (2004). Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis, 25: 1757-1769.

Morgan KT, Casey W, Easton M, Creech D, Ni H, Yoon L, Anderson S, Qualls C, Crosby LM, Bloomfield P, MacPherson A, and Elston T (2003). Frequent sampling reveals dynamic behavior throughout the transcriptome of HepG2 cells following nutrient replacement. Toxicol. Pathol., 31: 432-447.

Anderson SP, Yoon L, Richard EB, Cattley RC, and Corton JC (2002). Delayed liver regeneration in peroxisome proliferator-activated receptor- -null mice. Hepatology, 36: 1-11.

Morgan KT, Ni H, Brown HR, Yoon L, Qualls CW, Crosby LM, Reynolds R, Gaskill B, Anderson SP, Kepler TB, Brainard T, Liv N, Easton M, Merrill C, Creech D, Sprenger D, Conner G, Johnson PR, Fox TR, Sartor M, Richard EB, Kuruvilla S, Casey W, and Benavides G (2002). Application of cDNA microarray technology to in vitro toxicology and the selection of genes for a real-time RT-PCR based screen for oxidative stress in Hep-G2 cells. Toxicol. Pathol., 30: 435-451.

Casey W, Anderson S, Fox T, Dold K, Colton, H, and Morgan K (2002). Transcriptional and physiologic responses of HepG2 cells exposed to diethyl maleate: time course analysis. Physiol. Genomics, 8: 115-122.

Boorman GA, Anderson SP, Casey WM, Brown HR, Crosby LM, Gottschalk K, Easton M, Ni H, and Morgan KT (2002). Toxicogenomics, drug discovery, and the pathologist. Toxicol. Pathol. 30: 15-27.

Anderson SP, Dunn CS, Cattley RC, and Corton JC (2001). Hepatocellular proliferation in response to a peroxisome proliferator does not require TNF signaling. Carcinogenesis, 22: 1843-1851.

Corton JC, Anderson SP, and Stauber AJ (2000). Central role of peroxisome proliferator-activated receptors (PPARs) in the actions of peroxisome proliferators. Ann. Rev. Pharmacol. Toxicol., 40: 490-518.

Miller RT, Anderson SP, Corton JC, and Cattley RC (2000). Apoptosis, mitosis, and Cyp-40 expression in regressing peroxisome proliferator-induced adenomas. Carcinogenesis, 21: 647-652.

Anderson SP, Corton JC, and Cattley RC (1999). Hepatic expression of acute-phase protein genes during carcinogenesis induced by peroxisome proliferators. Mol. Carcinog., 26: 226-238.

Christensen JG, Romach EH, Healy LN, Gonzales AJ, Anderson SP, Malarkey DE, Corton JC, Fox TR, Cattley RC, and Goldsworthy TL (1999). Altered bcl-2 family expression during nongenotoxic hepatocarcinogenesis in mice. Carcinogenesis, 20: 1583-1590.

Corton JC, Fan L-Q, Brown S, Anderson SP, Bocos C, Cattley RC, and Gustafsson J-A (1998). Down-regulation of cytochrome P450 2C family members and positive acute-phase response gene expression by peroxisome proliferator chemicals. Mol. Pharmacol., 54: 463-473.

Briscoe WT, Anderson SP, and May HE (1990). Base sequence specificity of three 2-chloroethylnitrosoureas. Biochem. Pharmacol., 40: 1201-1209.

Manuscripts (not peer-reviewed)

Corton JC, Anderson SP, Stauber AJ, Janszen DB, Kimbell JS, and Conolly RB (1999). Entering the Era of Toxicogenomics with DNA Microarrays. CIIT Activities, 19(2): 1-9.

Anderson SP, Brenneman KA, Cattley RC, Everitt JI, Foster PMD, Kedderis GL, Kimbell JS, Recio L, Subramaniam RP, and Welsch F (1998). Research at CIIT on the risks to human health from exposure to chemicals. CIIT Activities, 18(10): 1-10.

Book Chapters

Corton JC and Anderson SP (2004). Using genetically altered mice in toxicogenomic analysis of chemical exposure. In Toxicogenomics: Principles and Applications. Hamadeh and Afshari (eds.). John Wiley & Sons, Hoboken, NJ.

Corton JC, Recio L, and Anderson SP (2002). Interpretation of toxicogenomic data using genetically altered mice. In Comprehensive Toxicology. Vanden Heuvel, Perdew, Mattes, and Greenlee (eds.). Elsevier Science, Amsterdam. Vol. XIV, pp 515-526.

Abstracts

Laughter A, Anderson SP, Dunn C, Yoon L, Swanson C, Chandraratna R, Stulnig TM, Steffensen KR, Gustaffson J, and Corton JC (2005). Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver. Toxicologist 84 (1-S), 57.

Anderson SP, Howroyd P, Liu J, Qian X, Bahnemann R, Swanson C, Kwak M, Kensler TW, and Corton JC (2005). The transcriptional response to a peroxisome proliferator-activated receptor alpha agonist includes increased expression of proteome maintenance genes. Toxicologist 84 (1-S), 58.

Corton JC, Apte U, Anderson SP, Limaye P, Yoon L, Latendresse J, Everitt J, Voss KA, Kimbrough C, Wong JS, Gill SS, Chandraratna R, Kwak M, Kensler TW, Stulnig TM, Steffensen KR, Gustaffson J, and Mehendale HM (2005). Role of PPAR-alpha in caloric restriction effects in the mouse liver. Toxicologist 84 (1-S), 59.

Xiao S, Anderson SP, Swanson C, Bahnemann R, Voss KA, Stauber AJ, and Corton JC (2005). Activation of peroxisome profilerator-activated receptor alpha enhances hepatocyte apoptosis. Toxicologist 84 (1-S), 2286.

Anderson SP, Swanson C, Everitt J, and Corton JC (2003). PPAR plays a major role in determining the gene expression profile altered by caloric restriction. Toxicologist 67 (1-S), 1652.

Corton JC, Anderson SP, Stauber A, Laughter A, Swanson C, Xiao S, Everitt J, and Voss K (2003). PPAR -dependent alterations in chemical-induced stress and longevity correlates with increased expression of heat shock proteins. Toxicologist 67 (1-S), 1650.

Voss K, Owen JR, Laughter A, Dunn C, Anderson SP, Riley R, Miller D and Corton JC (2003). The Role of the peroxisome proliferator-activated receptor alpha in modulating the effects of fumonisin B1 in mouse liver. Toxicologist 67 (1-S), 36.

Qualls CW, Hoivik DJ, Santostefano MJ, Brown HR, Anderson SP, Ott RJ, Boyce RW, Oliver BR, Mudd PN, and Miller RT (2003). Fibrates induce peroxisomal and mitochondrial proliferation in cynomolgus monkeys without causing cell cycle alterations or oxidative stress. Toxicologist 67 (1-S), 961.

Cornwell PD, Anderson SP, Bobashev G, and Corton JC (2002). Characterizing the mouse liver tumor response through expression profile analysis. Toxicologist 66 (1-S), 305.

Anderson SP, Richard EB, Ni H, Cattley RC, and Corton JC (2001). Gene Expression Profiling of Murine Hepatocarcinogenesis Induced by a Peroxisome Proliferator. Toxicol. Pathol. 29

Anderson SP, Dunn CS, Cattley RC, and Corton JC (2000). Hepatic mitogenesis and carcinogenesis induced by peroxisome proliferators is associated with alterations in IL-1 signaling pathways. Toxicol. Sci. 54 (1-S), 1976.

Liu J, Corton C, Liu Y, and Anderson S (1999). Microarray analysis of rodent

Contact this candidate